The FDA Might Be Thawing to THR: Here’s How It Could Move Faster
The FDA is showing early signs of potentially becoming more open to tobacco harm reduction (THR), with recent actions suggesting a shift in approach.Summary
The FDA appears to be cautiously shifting its stance on tobacco harm reduction (THR), a change advocates have long awaited. Historically, the agency has faced criticism for spreading misinformation about safer nicotine products and implementing a slow, politically influenced vape authorization process. Recent developments, including the authorization of nicotine pouches, the removal of a key official prioritizing youth prevention over adult access, and the approval of Juul vapes, signal a potential thaw. The FDA has launched a pilot program to streamline the review process for nicotine pouches, acknowledging the reduced risk compared to cigarettes and their potential as smoking cessation aids. A recent paper from the American Enterprise Institute (AEI) proposes 15 reforms to accelerate the authorization of safer nicotine products, including applying a 'least-burdensome' regulatory principle and improving communication with applicants. Experts emphasize the need for wider access to diverse nicotine products and public education on risk differentials, citing Sweden’s success in reducing smoking rates through low-risk oral nicotine products. While the FDA’s commitment remains to be seen, these changes offer a potential path towards a more effective approach to reducing smoking-related illnesses in the US.
(Source：Filter)
